FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Juliane Jürgensmeier

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Xenograft Model Antitumor Assays

Physiology

Anatomy

Disorders

Neovascularization, Pathologic

Phenomena

Blotting, Western

Concepts & Ideas

Treatment Outcome

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Jane Kendrew; Armelle Logié; Rajesh Odedra; Donald J Ogilvie; Sharon Pearsall; Paula J Taylor; Stephen R Wedge; Juliane M Jürgensmeier
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Sergey Popov; Safa Al-Sarraj; Lawrence Doey; Juliane M Jürgensmeier; Alexa Jury; Naga Kandasamy; Ross Laxton; Chris Jones
IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology.
Osamu Takahashi; Ignacio I Wistuba; Anderson Ryan; Paul D Smith; B Nebiyou Bekele; Anna Biernacka; Baruch Erez; Roy S Herbst; Keiko Hosho; Jörg J Jacoby; Juliane M Jürgensmeier; Ritsuko Komaki; Maria V Korshunova; Michael S O'Reilly
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Juliane Jürgensmeier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Jane Kendrew; Armelle Logié; Rajesh Odedra; Donald J Ogilvie; Sharon Pearsall; Paula J Taylor; Stephen R Wedge; Juliane M Jürgensmeier
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Cancer chemotherapy and pharmacology 2013;71(4):1021-32.
2013: Sergey Popov; Safa Al-Sarraj; Lawrence Doey; Juliane M Jürgensmeier; Alexa Jury; Naga Kandasamy; Ross Laxton; Chris Jones
IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology.
PloS one 2013;8(2):e56328.
2012: Osamu Takahashi; Ignacio I Wistuba; Anderson Ryan; Paul D Smith; B Nebiyou Bekele; Anna Biernacka; Baruch Erez; Roy S Herbst; Keiko Hosho; Jörg J Jacoby; Juliane M Jürgensmeier; Ritsuko Komaki; Maria V Korshunova; Michael S O'Reilly
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1641-54.
2012: Peter Mulders; Paul Nathan; Susanne Osanto; Laura Pike; Emilio Porfiri; Andrew Protheroe; C M L van Herpen; Igle de Jong; Robert Hawkins; Juliane M Jürgensmeier; Bijoyesh Mookerjee; Martin E Gore
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
European journal of cancer (Oxford, England : 1990) 2012;48(4):527-37.
2011: Sandra R Brave; Kirsty Ratcliffe; Zena Wilson; Neil H James; Sue Ashton; Anna Wainwright; Jane Kendrew; Philippa Dudley; Nicola Broadbent; Graham Sproat; Sian Taylor; Claire Barnes; Jeffrey C Silva; Charles L Farnsworth; Laurent Hennequin; Donald J Ogilvie; Juliane M Jürgensmeier; Masabumi Shibuya; Stephen R Wedge; Simon T Barry
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Molecular cancer therapeutics 2011;10(5):861-73.
2010: Neil R Smith; Dawn Baker; Neil H James; Kirsty Ratcliffe; Martin Jenkins; Susan E Ashton; Graham Sproat; Ruth Swann; Neil Gray; Anderson Ryan; Juliane M Jürgensmeier; Chris Womack
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(14):3548-61.
2010: Hester van Cruijsen; Emile E Voest; Cornelis J A Punt; Klaas Hoekman; Petronella O Witteveen; Martijn R Meijerink; Thomas A Puchalski; Jane Robertson; Owain Saunders; Juliane M Jürgensmeier; Carla M L van Herpen; Giuseppe Giaccone
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
European journal of cancer (Oxford, England : 1990) 2010;46(5):901-11.
2010: Walter Fiedler; Rolf M Mesters; Michael Heuser; Gerhard Ehninger; Wolfgang E Berdel; Ute Zirrgiebel; Jane D Robertson; Tom A Puchalski; Barbara Collins; Juliane M Jürgensmeier; Hubert Serve
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Leukemia research 2010;34(2):196-202.
2009: Michael Medinger; Norbert Esser; Ute Zirrgiebel; Anderson Ryan; Juliane M Jürgensmeier; Joachim Drevs
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Anticancer research 2009;29(12):5065-76.
2009: M Pia Morelli; Amy M Brown; Todd M Pitts; John J Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M Jürgensmeier; S Gail Eckhardt
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.
Molecular cancer therapeutics 2009;8(9):2546-58.
2009: Daniel P Bradley; Jean J Tessier; Tony Lacey; Marietta Scott; Juliane M Jürgensmeier; Rajesh Odedra; Jonathan Mills; Lyndsey Kilburn; Stephen R Wedge
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Magnetic resonance imaging 2009;27(3):377-84.
2009: Dietmar W Siemann; W D Brazelle; Juliane M Jürgensmeier
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
International journal of radiation oncology, biology, physics 2009;73(3):897-903.
2008: Caroline A Heckman; Tanja Holopainen; Maria Wirzenius; Salla Keskitalo; Michael Jeltsch; Seppo Ylä-Herttuala; Stephen R Wedge; Juliane M Jürgensmeier; Kari Alitalo
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Cancer research 2008;68(12):4754-62.
2007: Keiko Shibuya; Ritsuko Komaki; Tomoaki Shintani; Satoshi Itasaka; Anderson Ryan; Juliane M Jürgensmeier; Luka Milas; Kian Ang; Roy S Herbst; Michael S O'Reilly
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2007;69(5):1534-43.
2007: Neil R Smith; Neil H James; Ian Oakley; Anna Wainwright; Clive Copley; Jane Kendrew; Lynsey M Womersley; Juliane M Jürgensmeier; Stephen R Wedge; Simon T Barry
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Molecular cancer therapeutics 2007;6(8):2198-208.
2007: Joachim Drevs; Patrizia Siegert; Michael Medinger; Klaus Mross; Ralph Strecker; Ute Zirrgiebel; Jan Harder; Hubert Blum; Jane Robertson; Juliane M Jürgensmeier; Thomas A Puchalski; Helen Young; Owain Saunders; Clemens Unger
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3045-54.
2005: Katarina Kågedal; Ann-Charlotte Johansson; Uno Johansson; Gerd Heimlich; Karin Roberg; Nancy S Wang; Juliane M Jürgensmeier; Karin Ollinger
Lysosomal membrane permeabilization during apoptosis--involvement of Bax?
International journal of experimental pathology 2005;86(5):309-21.
2005: Stephen R Wedge; Jane Kendrew; Laurent F A Hennequin; Paula J Valentine; Simon T Barry; Sandra R Brave; Neil R Smith; Neil H James; Michael Dukes; Jon O Curwen; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Lyndsey L Kilburn; Sharon Barnett; Graham H P Richmond; Peter F Wadsworth; Mike Walker; Alison L Bigley; Sian T Taylor; Lee Cooper; Sarah Beck; Juliane M Jürgensmeier; Donald J Ogilvie
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Cancer research 2005;65(10):4389-400.
2004: Gerd Heimlich; Alastair D McKinnon; Katussevani Bernardo; Dieter Brdiczka; John C Reed; Renate Kain; Martin Krönke; Juliane M Jürgensmeier
Bax-induced cytochrome c release from mitochondria depends on alpha-helices-5 and -6.
The Biochemical journal 2004;378(Pt 1):247-55.
2004: Lucy T C Peltenburg; Elza C de Bruin; Dorothea Meersma; Saskia Wilting; Juliane M Jürgensmeier; Peter I Schrier
c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers.
Melanoma research 2004;14(1):3-12.
2002: Hamid Kashkar; Martin Krönke; Juliane M Jürgensmeier
Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis.
Cell death and differentiation 2002;9(7):750-7.
1997: Juliane M Jürgensmeier; Georg Bauer
Interference of bcl-2 with intercellular control of carcinogenesis.
International journal of cancer. Journal international du cancer 1997;71(4):698-704.
1997: Juliane M Jürgensmeier; J Panse; R Schäfer; Georg Bauer
Reactive oxygen species as mediators of the transformed phenotype.
International journal of cancer. Journal international du cancer 1997;70(5):587-9.
1996: C Langer; Juliane M Jürgensmeier; Georg Bauer
Reactive oxygen species act at both TGF-beta-dependent and -independent steps during induction of apoptosis of transformed cells by normal cells.
Experimental cell research 1996;222(1):117-24.
1995: D Schaefer; Juliane M Jürgensmeier; Georg Bauer
Catechol interferes with TGF-beta-induced elimination of transformed cells by normal cells: implications for the survival of transformed cells during carcinogenesis.
International journal of cancer. Journal international du cancer 1995;60(4):520-6.
1994: Juliane M Jürgensmeier; C P Schmitt; E Viesel; P Höfler; Georg Bauer
Transforming growth factor beta-treated normal fibroblasts eliminate transformed fibroblasts by induction of apoptosis.
Cancer research 1994;54(2):393-8.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.